# Single-ascending Dose Study of Kylo-11 in Healthy Subjects

> **NCT06363851** · PHASE1 · COMPLETED · sponsor: **Kylonova (Xiamen) Biopharma co., LTD.** · enrollment: 71 (actual)

## Conditions studied

- Cardiovascular Diseases

## Interventions

- **DRUG:** Kylo-11
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06363851
- **Lead sponsor:** Kylonova (Xiamen) Biopharma co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-16
- **Primary completion:** 2025-06-17
- **Final completion:** 2025-12-07
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06363851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06363851, "Single-ascending Dose Study of Kylo-11 in Healthy Subjects". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06363851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*